IRIDEX Company Profile (NASDAQ:IRIX)


IRIDEX logoIRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company's ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.

Industry, Sector and Symbol:
  • Sector: Computer and Technology
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Symbol: NASDAQ:IRIX
  • CUSIP: N/A
  • Web:
  • Market Cap: $104.01 million
  • Outstanding Shares: 11,544,000
Average Prices:
  • 50 Day Moving Avg: $10.12
  • 200 Day Moving Avg: $13.18
  • 52 Week Range: $8.70 - $16.64
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -31.07
  • P/E Growth: -0.59
Sales & Book Value:
  • Annual Revenue: $44.71 million
  • Price / Sales: 2.33
  • Book Value: $3.45 per share
  • Price / Book: 2.61
  • EBIDTA: ($3,520,000.00)
  • Net Margins: -1.01%
  • Return on Equity: -1.34%
  • Return on Assets: -1.08%
  • Current Ratio: 4.16%
  • Quick Ratio: 2.48%
  • Average Volume: 42,564 shs.
  • Beta: 1.16
  • Short Ratio: 10.49

Frequently Asked Questions for IRIDEX (NASDAQ:IRIX)

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Wednesday, May, 3rd. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The company had revenue of $10.48 million for the quarter, compared to the consensus estimate of $10.62 million. IRIDEX had a negative return on equity of 1.34% and a negative net margin of 1.01%. View IRIDEX's Earnings History.

When will IRIDEX make its next earnings announcement?

IRIDEX is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for IRIDEX.

Where is IRIDEX's stock going? Where will IRIDEX's stock price be in 2017?

2 brokerages have issued 12 month price objectives for IRIDEX's stock. Their forecasts range from $20.00 to $20.00. On average, they expect IRIDEX's share price to reach $20.00 in the next twelve months. View Analyst Ratings for IRIDEX.

Who are some of IRIDEX's key competitors?

Who are IRIDEX's key executives?

IRIDEX's management team includes the folowing people:

  • William M. Moore Jr., Chairman of the Board, Interim President and Chief Executive Officer
  • Atabak Mokari, Chief Financial Officer, Vice President - Corporate Development
  • George R. Marcellino PhD, Director
  • Sanford Fitch, Independent Director
  • Ruediger Naumann-Etienne Ph.D., Independent Director

Who owns IRIDEX stock?

IRIDEX's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.39%), Lyon Street Capital LLC (3.10%), Dimensional Fund Advisors LP (1.78%), Renaissance Technologies LLC (1.74%), Next Century Growth Investors LLC (1.17%) and Morgan Stanley (0.42%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, George R Marcellino, James H Mackaness, Romeo R Dizon, Ronald Steckel, Ruediger Naumann-Etienne and William M Moore. View Institutional Ownership Trends for IRIDEX.

Who sold IRIDEX stock? Who is selling IRIDEX stock?

IRIDEX's stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Next Century Growth Investors LLC and Morgan Stanley. Company insiders that have sold IRIDEX stock in the last year include George R Marcellino, Romeo R Dizon, Ronald Steckel and Ruediger Naumann-Etienne. View Insider Buying and Selling for IRIDEX.

Who bought IRIDEX stock? Who is buying IRIDEX stock?

IRIDEX's stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Vanguard Group Inc., Geode Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon and William M Moore. View Insider Buying and Selling for IRIDEX.

How do I buy IRIDEX stock?

Shares of IRIDEX can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is IRIDEX's stock price today?

One share of IRIDEX stock can currently be purchased for approximately $9.01.

MarketBeat Community Rating for IRIDEX (NASDAQ IRIX)
Community Ranking:  1.8 out of 5 ()
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  21 (Vote Underperform)
Total Votes:  33
MarketBeat's community ratings are surveys of what our community members think about IRIDEX and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for IRIDEX (NASDAQ:IRIX) (?)
Ratings Breakdown: 1 Sell Rating, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $20.00 (121.98% upside)

Analysts' Ratings History for IRIDEX (NASDAQ:IRIX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017ValuEngineDowngradeSell -> Strong SellLowView Rating Details
12/21/2016Roth CapitalInitiated CoverageBuy$20.00N/AView Rating Details
1/26/2016Singular ResearchInitiated CoverageBuy$11.50N/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for IRIDEX (NASDAQ:IRIX)
Earnings by Quarter for IRIDEX (NASDAQ:IRIX)
Earnings History by Quarter for IRIDEX (NASDAQ:IRIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2017Q1 2017($0.18)($0.16)$10.62 million$10.48 millionViewListenView Earnings Details
11/3/2016Q316($0.03)($0.07)$11.20 million$9.79 millionViewListenView Earnings Details
8/4/2016Q216$0.01($0.03)$11.90 million$11.90 millionViewListenView Earnings Details
5/5/2016Q116$0.04$0.01$11.88 million$11.90 millionViewListenView Earnings Details
3/3/2016Q415$0.04$0.04$11.80 million$12.10 millionViewListenView Earnings Details
11/5/2015Q315$0.04$10.10 million$9.80 millionViewListenView Earnings Details
8/6/2015Q215($0.07)$10.60 million$9.00 millionViewListenView Earnings Details
5/7/2015Q115$0.02$10.30 million$10.80 millionViewListenView Earnings Details
5/1/2014Q1$0.06$0.05$8.90 million$10.30 millionViewListenView Earnings Details
2/27/2014Q4$0.04$0.04ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for IRIDEX (NASDAQ:IRIX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.18)($0.18)($0.18)
Q2 20171($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for IRIDEX (NASDAQ:IRIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for IRIDEX (NASDAQ:IRIX)
Insider Ownership Percentage: 26.40%
Institutional Ownership Percentage: 40.15%
Insider Trades by Quarter for IRIDEX (NASDAQ:IRIX)
Institutional Ownership by Quarter for IRIDEX (NASDAQ:IRIX)
Insider Trades by Quarter for IRIDEX (NASDAQ:IRIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2017Romeo R DizonInsiderSell2,811$13.16$36,992.76View SEC Filing  
11/16/2016Romeo R DizonInsiderSell584$16.04$9,367.36View SEC Filing  
9/12/2016Romeo R DizonInsiderSell125$15.00$1,875.00View SEC Filing  
9/7/2016Ruediger Naumann-EtienneDirectorSell9,513$14.75$140,316.75View SEC Filing  
9/2/2016Ruediger Naumann-EtienneDirectorSell2,513$14.73$37,016.49View SEC Filing  
8/23/2016Romeo R DizonInsiderSell875$14.52$12,705.00View SEC Filing  
8/19/2016Romeo R DizonInsiderSell7,896$13.52$106,753.92View SEC Filing  
8/16/2016George R MarcellinoDirectorSell2,513$13.57$34,101.41View SEC Filing  
8/16/2016Romeo R DizonInsiderSell839$13.70$11,494.30View SEC Filing  
6/6/2016Ronald SteckelVPSell625$13.52$8,450.00View SEC Filing  
5/17/2016Ronald SteckelVPSell4,583$12.81$58,708.23View SEC Filing  
3/8/2016Ronald SteckelVPSell12,000$10.45$125,400.00View SEC Filing  
11/19/2015William M MooreCEOBuy10,000$9.83$98,300.00View SEC Filing  
9/25/2015Associates & Paragon A ParagonMajor ShareholderBuy52,042$7.05$366,896.10View SEC Filing  
9/10/2015Associates & Paragon A ParagonMajor ShareholderBuy11,866$6.95$82,468.70View SEC Filing  
9/4/2015Associates & Paragon A ParagonMajor ShareholderBuy10,304$6.81$70,170.24View SEC Filing  
9/2/2015Ronald SteckelVPSell1,875$6.80$12,750.00View SEC Filing  
8/21/2015Associates & Paragon A ParagonMajor ShareholderBuy20,651$7.16$147,861.16View SEC Filing  
8/19/2015James H. MackanessCFOSell2,373$7.15$16,966.95View SEC Filing  
8/19/2015Ronald SteckelVPSell1,751$7.14$12,502.14View SEC Filing  
8/18/2015James H. MackanessCFOSell2,627$7.10$18,651.70View SEC Filing  
8/17/2015James H. MackanessCFOSell2,235$7.05$15,756.75View SEC Filing  
8/14/2015James H MackanessCFOSell7,765$6.99$54,277.35View SEC Filing  
8/14/2015Ronald SteckelVPSell1,458$7.00$10,206.00View SEC Filing  
7/24/2015Associates & Paragon A ParagonMajor ShareholderBuy40,403$7.01$283,225.03View SEC Filing  
6/17/2015Ronald SteckelVPSell1,666$8.77$14,610.82View SEC Filing  
5/20/2015James H MackanessCFOSell2,000$9.80$19,600.00View SEC Filing  
5/18/2015Ronald SteckelVPSell1,667$9.33$15,553.11View SEC Filing  
4/20/2015Ronald SteckelVPSell1,447$9.79$14,166.13View SEC Filing  
4/17/2015Ronald SteckelVPSell1,667$9.86$16,436.62View SEC Filing  
3/17/2015Ronald SteckelVPSell11,358$10.08$114,488.64View SEC Filing  
3/10/2015Ronald SteckelVPSell1,250$10.03$12,537.50View SEC Filing  
2/17/2015Ronald SteckelVPSell1,650$9.79$16,153.50View SEC Filing  
1/20/2015Ronald SteckelVPSell1,650$9.03$14,899.50View SEC Filing  
12/17/2014Ronald SteckelVPSell1,650$8.52$14,058.00View SEC Filing  
11/17/2014Ronald SteckelVPSell1,650$8.28$13,662.00View SEC Filing  
11/6/2014William M MooreDirectorBuy5,000$7.79$38,950.00View SEC Filing  
10/12/2014Catalyst Fund Ix L.P BluelineDirectorBuy17,237$8.11$139,792.07View SEC Filing  
10/10/2014Catalyst Fund Ix L.P BluelineDirectorBuy12,798$8.02$102,639.96View SEC Filing  
9/5/2014Catalyst Fund Ix L.P BluelineDirectorBuy8,432$7.99$67,371.68View SEC Filing  
8/29/2014Catalyst Fund Ix L.P BluelineDirectorBuy4,272$7.92$33,834.24View SEC Filing  
8/22/2014James B HawkinsDirectorSell600$8.03$4,818.00View SEC Filing  
8/18/2014Ronald SteckelVPSell1,650$8.00$13,200.00View SEC Filing  
8/15/2014James B HawkinsDirectorSell14,400$8.10$116,640.00View SEC Filing  
8/14/2014James B HawkinsDirectorSell2,714$8.08$21,929.12View SEC Filing  
8/13/2014James B HawkinsDirectorSell9,786$8.11$79,364.46View SEC Filing  
8/11/2014Garrett A GarrettsonDirectorSell2,810$8.30$23,323.00View SEC Filing  
7/31/2014Ronald SteckelVPSell761$8.00$6,088.00View SEC Filing  
7/21/2014James H MackanessCFOSell1,000$7.62$7,620.00View SEC Filing  
6/23/2014James H MackanessCFOSell2,000$8.24$16,480.00View SEC Filing  
6/17/2014Ronald SteckelVPSell1,650$8.20$13,530.00View SEC Filing  
6/6/2014Catalyst Fund Ix L.P BluelineDirectorBuy7,390$8.32$61,484.80View SEC Filing  
6/3/2014William M MooreCEOBuy5,000$8.48$42,400.00View SEC Filing  
5/21/2014James H MackanessCFOSell3,000$8.73$26,190.00View SEC Filing  
5/19/2014Ronald SteckelVPSell1,650$8.82$14,553.00View SEC Filing  
5/9/2014William M MooreCEOBuy5,000$8.40$42,000.00View SEC Filing  
4/22/2014James H MackanessCFOSell4,000$8.74$34,960.00View SEC Filing  
4/17/2014Ronald SteckelVPSell1,650$8.88$14,652.00View SEC Filing  
3/21/2014James H MackanessCFOSell4,000$9.03$36,120.00View SEC Filing  
3/17/2014Ronald SteckelVPSell1,650$9.07$14,965.50View SEC Filing  
2/18/2014Ronald SteckelVPSell1,650$8.60$14,190.00View SEC Filing  
1/17/2014Ronald SteckelVPSell1,650$10.42$17,193.00View SEC Filing  
12/17/2013Ronald SteckelVPSell1,650$8.56$14,124.00View SEC Filing  
12/2/2013James H MackanessCFOSell10,000$10.52$105,200.00View SEC Filing  
9/6/2013Ruediger Naumann-EtienneDirectorBuy3,600$5.99$21,564.00View SEC Filing  
8/9/2013William M MooreCEOBuy10,000$5.88$58,800.00View SEC Filing  
6/19/2013Eduardo AriasVPSell22,768$5.43$123,630.24View SEC Filing  
6/18/2013James H MackanessCFOSell19,862$4.58$90,967.96View SEC Filing  
6/17/2013Eduardo AriasVPSell4,532$5.39$24,427.48View SEC Filing  
6/14/2013James H MackanessCFOSell10,568$5.38$56,855.84View SEC Filing  
6/13/2013James H MackanessCFOSell1,400$5.30$7,420.00View SEC Filing  
6/11/2013Eduardo AriasVPSell1,000$5.61$5,610.00View SEC Filing  
6/11/2013James H MackanessCFOSell1,200$5.61$6,732.00View SEC Filing  
6/10/2013Eduardo AriasVPSell2,400$5.38$12,912.00View SEC Filing  
6/10/2013James H MackanessCFOSell6,970$5.36$37,359.20View SEC Filing  
6/6/2013William M MooreCEOBuy2,000$5.42$10,840.00View SEC Filing  
5/17/2013Eduardo AriasVPSell10,000$6.30$63,000.00View SEC Filing  
3/8/2013Ruediger Naumann-EtienneDirectorBuy2,400$4.80$11,520.00View SEC Filing  
3/7/2013William M MooreCEOBuy10,000$4.66$46,600.00View SEC Filing  
9/6/2012William M MooreCEOBuy10,000$3.76$37,600.00View SEC Filing  
8/15/2012Catalyst Fund Ix L.P BluelineMajor ShareholderBuy60,900$3.19$194,271.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for IRIDEX (NASDAQ:IRIX)
Latest Headlines for IRIDEX (NASDAQ:IRIX)
DateHeadline logoIRIDEX To Present At The Jefferies 2017 Global Healthcare Conference - May 24 at 5:55 PM logoIRIDEX Co. (IRIX) Stock Rating Lowered by ValuEngine - May 16 at 4:00 PM logoIRIDEX Co. (IRIX) Upgraded by Zacks Investment Research to Hold - May 12 at 12:06 AM logoIRIDEX Co. (IRIX) Upgraded at Zacks Investment Research - May 5 at 12:00 AM logoInvestor Network: IRIDEX Corporation to Host Earnings Call - May 4 at 6:08 PM logoIRIDEX Announces Presentation Of Data Demonstrating Safety And Efficacy Of Micropulse® Technology At Upcoming Industry Conferences - May 4 at 6:08 PM logoEdited Transcript of IRIX earnings conference call or presentation 3-May-17 9:30pm GMT - May 4 at 11:29 AM logoIRIDEX Announces First Quarter 2017 Financial Results - May 3 at 10:46 PM logoIridex reports 1Q loss - May 3 at 6:05 PM logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating IRIDEX Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors - May 1 at 1:16 PM logoIRIDEX (IRIX) Earning Somewhat Favorable Press Coverage, AlphaOne Reports - April 28 at 10:28 PM logoSomewhat Positive Media Coverage Somewhat Likely to Impact IRIDEX (IRIX) Stock Price - April 21 at 11:30 PM logoIRIDEX to Report First Quarter 2017 Financial Results on May 3, 2017 - April 19 at 10:50 PM logoIRIDEX (IRIX) Getting Favorable Press Coverage, Study Shows - April 18 at 6:51 PM logoIRIDEX Co. (IRIX) Downgraded to "D+" at TheStreet - April 17 at 12:52 AM logoIRIDEX (IRIX) Getting Favorable Media Coverage, Report Shows - April 13 at 3:12 PM logoETFs with exposure to IRIDEX Corp. : April 7, 2017 - April 7 at 5:50 PM logoRoth Capital Weighs in on IRIDEX Co.'s Q1 2017 Earnings (IRIX) - March 23 at 9:47 AM logoEdited Transcript of IRIX earnings conference call or presentation 8-Mar-17 10:00pm GMT - March 17 at 8:58 AM logoIRIDEX To Present At The Sidoti & Co. Spring 2017 Convention - March 15 at 6:16 PM logoIRIDEX CORP Files SEC form 10-K, Annual Report - March 15 at 6:16 PM logoIRIDEX CORP Files SEC form 8-K, Change in Directors or Principal Officers - March 13 at 5:49 PM logoQ4 2016 IRIDEX Corp Earnings Release - After Market Close - March 8 at 6:44 PM logoIRIDEX Announces Fourth Quarter and 2016 Financial Results and Provides Full Year 2017 Financial Outlook - March 8 at 6:44 PM logo8:03 am IRIDEX announces the availability of the G-Probe Illuminate, a new, FDA-cleared probe offering combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (:CPC) - February 28 at 6:08 PM logoIRIDEX To Present At 29th Annual Roth Conference - February 28 at 6:08 PM logoIRIDEX Launches New FDA-Cleared Probe At The Annual American Glaucoma Society Meeting - February 28 at 9:24 AM logoIRIDEX to Report Fourth Quarter and 2016 Financial Results on March 8, 2017 - February 22 at 6:13 PM logoIRIDEX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - January 10 at 6:51 PM logoIRIDEX Announces Preliminary Unaudited Revenues for 2016 Fourth Quarter and Full Year - January 9 at 6:44 PM logoIRIDEX announces preliminary revenues for Q4 and FY2016 - January 9 at 6:44 PM logoCoverage initiated on IRIDEX by ROTH Capital - December 21 at 6:50 PM logoIRIDEX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex - December 14 at 6:37 PM logoIRIDEX Corporation Prices Public Offering of Common Stock - December 9 at 9:48 AM logoETFs with exposure to IRIDEX Corp. : December 8, 2016 - December 8 at 6:35 PM logoIRIDEX Corporation Announces Proposed Public Offering of Common Stock - December 8 at 6:35 PM logo4:32 pm IRIDEX to offer newly issued shares of common stock pursuant to an underwritten public offering; size not disclosed - December 8 at 6:35 PM logoEdited Transcript of IRIX earnings conference call or presentation 3-Nov-16 9:00pm GMT - November 23 at 5:42 PM logoIRIDEX CORP Financials - November 19 at 8:16 AM logoIRIDEX CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits - November 9 at 5:22 PM logoIRIDEX to Present at Upcoming Investor Conferences - November 7 at 6:02 PM logoQ3 2016 IRIDEX Corp Earnings Release - After Market Close - November 3 at 9:08 AM logoIRIDEX Announces Preliminary Revenues for 2016 Third Quarter - October 12 at 5:41 PM logoIridex Corp (IRIX) Prelim. Q3 Revenue Misses Expectations - October 12 at 5:41 PM logoHumana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday - October 12 at 5:41 PM logoEdited Transcript of IRIX earnings conference call or presentation 4-Aug-16 9:00pm GMT - August 15 at 9:16 PM logoQ2 2016 IRIDEX Corp Earnings Release - After Market Close - August 4 at 8:44 AM logoIRIDEX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Definitive Agre - July 11 at 4:17 PM logoIRIDEX CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders - June 21 at 4:17 PM logoQ1 2016 IRIDEX Corp Earnings Release - After Market Close - May 5 at 7:07 AM



IRIDEX (IRIX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff